Patent intelligence · US
US 12329829
Kit for radiolabelling with 68GA comprising a metal inhibitor
Kit for radiolabelling with 68GA comprising a metal inhibitor
Patent details — US 12329829
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jun 17, 2025
- Expiration
- Jun 12, 2045
- Applicant
- Telix Innovations S.A.
- Claims
- 3
- CPC classes
- A61K, A61K51/0482, A61K51/0497, A61K51/08
Quick answer
US 12329829 (Kit for radiolabelling with 68GA comprising a metal inhibitor) is held by Telix Innovations S.A.. Status: granted. Granted Jun 17, 2025. Expires Jun 12, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Telix Innovations S.A.
- Grant date
- Expiration
- Claims
- 3
- CPC classes
- A61K, A61K51/0482, A61K51/0497, A61K51/08
More from Telix Innovations S.A.
Related pharmaceutical patents in our USPTO index.
Frequently asked questions
What is US patent 12329829?
US 12329829 (Kit for radiolabelling with 68GA comprising a metal inhibitor) is held by Telix Innovations S.A.. Status: granted. Granted Jun 17, 2025. Expires Jun 12, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12329829?
Telix Innovations S.A. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 3 pharmaceutical patents for this assignee.
When does US 12329829 expire?
Our index shows an expiration date of Jun 12, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.